13 Nov

Today, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) released a report titled Global Participation in Clinical Trials: 2015-2019. The report summarizes CDER’s Drug Trials Snapshot program by illustrating the demographic groups represented in the clinical trials for new drug approvals from 2015-2019. Overall, almost 300,000 patients participated in these trials, and 35 percent were from the United States (U.S.). The summary provides an overall participation of each demographic group globally and within the United States followed by participation trends over the 5-year span and by therapeutic areas. CDER released past annual summary reports of Drug Trials Snapshots, but this is the first summary report to cover five years’ worth of DTS data.

Today, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) released a report titled Global Participation in Clinical Trials: 2015-2019. The report summarizes CDER’s Drug Trials Snapshot program by illustrating the demographic groups represented in the clinical trials for new drug approvals from 2015-2019. Overall, almost 300,000 patients participated in these trials, and 35 percent were from the United States (U.S.). The summary provides an overall participation of each demographic group globally and within the United States followed by participation trends over the 5-year span and by therapeutic areas. CDER released past annual summary reports of Drug Trials Snapshots, but this is the first summary report to cover five years’ worth of DTS data.

Today, the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) released a report titled Global Participation in Clinical Trials: 2015-2019. The report summarizes CDER’s Drug Trials Snapshot program by illustrating the demographic groups represented in the clinical trials for new drug approvals from 2015-2019. Overall, almost 300,000 patients participated in these trials, and 35 percent were from the United States (U.S.). The summary provides an overall participation of each demographic group globally and within the United States followed by participation trends over the 5-year span and by therapeutic areas. CDER released past annual summary reports of Drug Trials Snapshots, but this is the first summary report to cover five years’ worth of DTS data.

Relatedly, on December 16, 2020, CDER will host a webinar on “Diversity in Clinical Trials.”Topics covered in this webinar will include: FDA guidance that supports diverse participation in clinical trials, status of trial diversity after 5 years of Drug Trials Snapshots reporting and FDA’s efforts that support clinical trial diversity. If you’d like to attend, please register in advance.

Source: USFDA

Comments
* The email will not be published on the website.